Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis

Immunotherapy is the newest approach to combat cancer. It can be achieved using several strategies, among which is the dendritic cell (DC) vaccine therapy. Several clinical trials are ongoing using DC vaccine therapy either as a sole agent or in combination with other interventions to tackle different types of cancer. Immunotherapy can offer a potential treatment to coronavirus disease 2019 (COVID-19) the worst pandemic facing this generation, a disease with deleterious effects on the health and economic systems worldwide. We hypothesize that DC vaccine therapy may provide a potential treatment strategy to help combat COVID-19. Cancer patients are at the top of the vulnerable population owing to their immune-compromised status. In this review, we discuss DC vaccine therapy in the light of the body's immunity, cancer, and newly emerging infections such as COVID-19 in hopes of better-customized treatment options for patients with multiple comorbidities.

Automated summary

Immunotherapy, particularly dendritic cell (DC) vaccine therapy, is a promising approach for combating cancer and potentially treating diseases like COVID-19. Clinical trials are ongoing to explore the efficacy of DC vaccine therapy in combination with other interventions. This personalized treatment option may benefit vulnerable populations, such as cancer patients with compromised immune systems.